I. COMMENCED TRADING IN FEBRUARY | ||||||||
Company |
Date |
Date |
Shares/ |
Price |
Shares |
Lead, Other |
Gross |
Post- |
| | ||||||||
INITIAL OFFERINGS | ||||||||
There were no initial public offerings conducted in February. | ||||||||
Total: $0M | ||||||||
Number of IPOs in February: 0 | ||||||||
Average value of February IPOs: $0M | ||||||||
Number of IPOs in 2003: 0 | ||||||||
Total raised in IPOs in 2003: $0M | ||||||||
Average value of IPOs in 2003: $0M | ||||||||
| ||||||||
FOLLOW-ON OFFERINGS | ||||||||
Company |
Date |
Date |
Shares/ |
Price |
Shares |
Lead, Other |
Gross |
Post- |
| | ||||||||
|
BioMarin Pharmaceutical Inc. (BMRN)1 |
12/23/02 |
2/21/03 |
7.5S |
$10 |
61.3 |
UBS Warburg (lead) CIBC World Markets SG Cowen Securities |
$75 |
$613 |
OVERALLOTMENT OPTIONS EXERCISED | ||||||||
|
AtheroGenics Inc. (AGIX)2 |
11/13/02 |
2/3/03 |
$6.25 |
36.4 |
Morgan Stanley Lehman Brothers Lazard Freres Adams, Harkness & Hill |
$6.875 |
$227.5 |
|
|
||||||||
Total: $81.875M | ||||||||
Number of follow-on offerings in February: 1 | ||||||||
Average value of February follow-ons: $81.875M | ||||||||
Number of follow-on offerings in 2003: 4 | ||||||||
Total raised in follow-ons in 2003: $336.055M | ||||||||
Average value of follow-ons in 2003: $84.01M | ||||||||
|
| ||||||||
Notes: | ||||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||||||
@ This column reflects the shares outstanding following the offering, when disclosed. | ||||||||
% Market capitalization calculated is based on the offering price. | ||||||||
1. BioMarin raised $75M with the issuance of 7.5M shares. The company originally filed to sell 6M shares in February as part of its previously filed shelf registration statement. Underwriters have an option to purchase 1.125M additional shares to cover overallotments. | ||||||||
2. AtheroGenics' underwriters exercised their overallotment option for 1.1M shares of common stock. The offering raised a total of $51.875M. | ||||||||
| ||||||||
II. FILED AND PENDING | ||||||
Company |
Date |
Shares/ |
Price Range |
Shares Out (M)@ |
Lead, Other |
Value |
| | ||||||
INITIAL OFFERINGS | ||||||
|
MitoKor Inc. |
3/8/02 |
N/A |
N/A |
N/A |
RBC Capital Markets Lazard Freres Legg Mason Wood Walker Gerard Klauer Mattison |
$60 |
|
||||||
|
Stem Genetics |
7/18/02 |
1.5S |
$7 |
32.3 |
Self-underwritten |
$10.5 |
| ||||||
|
ViaCell Inc. |
1/30/02 |
N/A |
N/A |
N/A |
UBS Warburg Banc of America Securities U.S. Bancorp Piper Jaffray |
$115 |
|
|
|||||
FOLLOW-ON OFFERINGS | ||||||
|
Aphton Corp. |
7/8/02 |
5S |
$6.50 |
25.1 |
N/A |
$32.5 |
| ||||||
|
Ariad |
1/9/02 |
3S |
$5.28 |
35.4 |
N/A |
$15.84 |
| ||||||
|
Biomira Inc. |
5/2/02 |
N/A |
N/A |
53.4 |
N/A |
C$150 (US$97.84) |
| ||||||
|
Bioxel Pharma |
11/11/02 |
14.3S |
C$0.70 |
N/A |
Dundee Securities National Bank Financial Canaccord Capital |
C$10 (US$6.7) |
|
|
|||||
|
Celgene Corp. |
12/21/01 |
N/A |
N/A |
75.6 |
N/A |
$500 |
| ||||||
|
Cell Genesys Inc. |
12/23/02 |
N/A |
N/A |
N/A |
N/A |
$150 |
| ||||||
|
Cell Pathways |
2/7/01 |
N/A |
N/A |
N/A |
N/A |
$25 |
| ||||||
|
Centrex Inc. |
2/24/03 |
N/A |
N/A |
N/A |
HD Brous & Co. Inc. |
$20 |
| ||||||
|
Cepheid Inc. |
12/21/01 |
N/A |
N/A |
26.56 |
N/A |
$35 |
| ||||||
|
Cerus Corp. |
8/13/01 |
N/A |
N/A |
15.7 |
N/A |
$300 |
| ||||||
|
CollaGenex |
10/26/01 |
0.965S |
$8.01 |
N/A |
Kingsbridge Capital Prentice Securities |
$7.7 |
| ||||||
|
Cytogen Corp. |
10/26/01 |
10S |
$2.50 |
79.8 |
N/A |
$25 |
| ||||||
|
Dendreon Corp. |
1/22/03 |
N/A |
N/A |
N/A |
N/A |
$75 |
| ||||||
|
Dyax Corp. |
4/25/02 |
5S |
$3.66 |
19.6 |
N/A |
$18.3 |
| ||||||
|
EntreMed Inc. |
5/10/02 |
N/A |
N/A |
N/A |
N/A |
$50 |
| ||||||
|
Exelixis Inc. |
7/30/01 |
N/A |
N/A |
49.2 |
N/A |
$150 |
| ||||||
|
Genaera Corp. |
11/21/01 |
N/A |
N/A |
38.9 |
N/A |
$50 |
| ||||||
|
Genaissance |
10/18/01 |
N/A |
N/A |
22.8 |
N/A |
$35 |
| ||||||
|
GenVec Inc. |
12/19/02 |
N/A |
N/A |
N/A |
N/A |
$25 |
| ||||||
|
Geron Corp. |
1/30/02 |
N/A |
N/A |
N/A |
N/A |
$150 |
| ||||||
|
Hemispherx |
1/15/03 |
5S |
$2.16 |
37.6 |
N/A |
$10.8 |
| ||||||
|
Hollis-Eden |
2/26/02 |
3S |
$8.71 |
N/A |
N/A |
$26.13 |
| ||||||
|
InSite Vision |
2/2/01 |
N/A |
N/A |
N/A |
Ladenburg Thalmann (placement agent) |
$40 |
|
||||||
|
Inspire |
1/21/03 |
N/A |
N/A |
N/A |
N/A |
$100 |
| ||||||
|
Lexicon Genetics |
11/27/02 |
12S |
$3.98 |
N/A |
N/A |
$47.76 |
| ||||||
|
Martek |
2/4/03 |
N/A |
N/A |
N/A |
N/A |
$100 |
| ||||||
|
Neurogen Corp. |
8/16/02 |
N/A |
N/A |
N/A |
N/A |
$75 |
| ||||||
|
Northwest |
6/4/02 |
11S |
$3.77 |
17 |
C.E. Unterberg, Towbin |
$41.5 |
| ||||||
|
Pharmos Corp. |
2/4/02 |
N/A |
N/A |
56.6 |
N/A |
$25 |
| ||||||
|
SciClone |
11/6/01 |
N/A |
N/A |
N/A |
N/A |
$20 |
| ||||||
|
Spectrum |
1/3/01 |
N/A |
N/A |
26.9 |
N/A |
$50 |
| ||||||
|
StemCells Inc. (STEM)35 |
3/8/02 |
15S |
$2.52 |
25.8 |
N/A |
$37.8 |
| ||||||
|
Targeted |
12/13/01 |
8.84S |
$2.57 |
N/A |
N/A |
$22.72 |
| ||||||
|
Triangle |
9/25/02 |
N/A |
N/A |
N/A |
N/A |
$80 |
| ||||||
|
Tularik Inc. |
8/14/01 |
N/A |
N/A |
49.2 |
N/A |
$250 |
| ||||||
|
VaxGen Inc. |
11/7/02 |
N/A |
N/A |
N/A |
N/A |
$150 |
| ||||||
III. WITHDRAWN AND POSTPONED | ||||||
Company |
Date |
Shares/ |
Price |
Shares |
Lead, Other |
Value |
| | ||||||
FOLLOW-ON OFFERINGS | ||||||
|
Antex |
10/25/02 2/27/03 |
8U |
$0.75 |
20.4 |
Roan/Meyers & Associates |
$6 |
| ||||||
|
Epimmune Inc. |
10/24/02 2/12/03 |
7.25S |
$1.32 |
19.4 |
Punk Ziegel & Co. (placement agent) |
$9.57 |
|
| ||||||
Notes: | ||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||||
* Stock symbols for companies seeking to complete IPOs are proposed. | ||||||
@ This column reflects the shares outstanding following the offering, when disclosed. | ||||||
N/A = Not available, applicable or reported. | ||||||
AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange | ||||||
1. MitoKor filed for an IPO to raise $60M. | ||||||
2. Stem Genetics filed for an IPO to raise $10.5M. It intends to go public on the Over-the-Counter Bulletin Board, but did not specify a proposed symbol in its SEC filing. | ||||||
3. ViaCell filed for a $115M IPO. No further details were disclosed. | ||||||
4. Aphton filed a shelf registration statement to sell up to 5M shares at a maximum amount of $6.50 per share. The company privately placed $5M in shares in September 2002 and $1.52M in shares in February 2003. | ||||||
5. Ariad filed a shelf registration statement to sell up to 3M shares. At the Jan. 8, 2002, closing stock price, it would raise $15.84M. | ||||||
6. Biomira filed for a $150M shelf prospectus in Canada. | ||||||
7. Bioxel filed a preliminary prospectus for a public offering of common shares in Canada. There will be an overallotment option for 15% of the shares offered. The company filed its final prospectus in February. | ||||||
8. Celgene filed a universal shelf registration statement to offer and sell common stock, debt securities and convertible debt securities, up to a total value of $500M. | ||||||
9. Cell Genesys filed a shelf registration statement allowing it to issue, from time to time, up to $150M of securities. | ||||||
10. Cell Pathways filed a shelf registration statement for the sale of $25M in common stock. The company privately placed $4.4M in shares in September 2002. | ||||||
11. Centrex plans to raised $20M with HD Brous as its managing underwriter. | ||||||
12. Cepheid filed a shelf registration statement to offer and sell up to $35M of its common stock, preferred stock, debt securities and warrants. | ||||||
13. Cerus filed to sell up to $300M of common stock and debt in a shelf offering. | ||||||
14. The value of CollaGenex's proposed offering, $7.7M, is based on the Oct. 26, 2001, closing stock price of $8.01. CollaGenex privately placed 119,335 shares in May 2002, raising $1M. It placed 32,187 shares in June 2002, raising $266,667. | ||||||
15. Cytogen filed to offer 10M shares at about $2.50 each in a shelf registration statement. It privately placed 3M shares in January 2002, and another 4.17M shares in June 2002. | ||||||
16. Dendreon filed a shelf registration statement with the SEC to sell $75M in stock from time to time | ||||||
17. Dyax filed a shelf registration statement to sell up to 5M shares. The value, $18.3M, is based on the April 24, 2002, closing stock price of $3.66. | ||||||
18. EntreMed filed a $50M shelf registration statement, allowing it to offer securities, from time to time, in the form of common stock, preferred stock or warrants to purchase securities. | ||||||
19. Exelixis filed a shelf registration statement to sell up to $150M in common stock. | ||||||
20. Genaera filed a universal shelf registration statement for the sale of up to $50M in common stock, preferred stock or warrants to purchase common stock or preferred stock. It privately placed $16.5M in shares in April 2002. | ||||||
21. Genaissance filed a shelf registration statement to offer and sell common stock, preferred stock, debt or warrants, up to a value of $35M. | ||||||
22. GenVec filed a $25M shelf registration statement with the SEC. | ||||||
23. Geron filed a prospectus for the sale of up to $150M in debt securities, common or preferred stock and warrants. | ||||||
24. Hemispherx filed to register 5M shares of common stock. The value, $10.8M, is based on the proposed maximum offering price. | ||||||
25. Hollis-Eden filed a shelf registration statement to sell up to 3M shares and warrants from time to time. The value is based on the proposed maximum offering price. | ||||||
26. InSite filed a shelf registration statement in February 2001 to sell $40M in stock. | ||||||
27. Inspire filed with the SEC a shelf registration statement to allow it to issue shares of common stock up to $100M. | ||||||
28. Lexicon Genetics filed a shelf registration statement with the SEC to sell up to an aggregate of 12M shares of common stock from time to time. The value, $47.76M, is based on the proposed maximum aggregate offering price per share, $3.98. | ||||||
29. Martek filed a shelf registration statement to raise up to $100M. | ||||||
30. Neurogen filed for a $75M universal shelf registration statement. | ||||||
31. Northwest expects to offer 11M shares as part of a lock-up agreement with the underwriter from the company's December 2001 initial public offering. The value, $41.5M, is based on the June 3, 2002, closing stock price of $3.77. | ||||||
32. Pharmos filed a shelf registration statement to sell up to $25M of common stock, preferred stock, debt securities and/or warrants. | ||||||
33. SciClone filed to sell up to $20M in common and preferred stock, debt securities and warrants, from time to time, through a shelf offering. SciClone privately placed $10.62M in shares in June 2002. | ||||||
34. Spectrum filed a shelf registration statement covering the sale of debt securities, common stock, preferred stock, depository shares or warrants up to $50M. Since May 2001, it has privately placed $27.65M. | ||||||
35. StemCells filed with the SEC to sell up to 15M shares to raise a maximum of $37.8M. Further details were not disclosed. | ||||||
36. Targeted Genetics filed a shelf registration statement for the sale of up to about 8.84M shares of common stock. The value is based on the Jan. 22, 2002, closing stock price of $2.57. | ||||||
37. Triangle filed a shelf registration statement with the SEC to sell up to $80M in common and preferred stock. | ||||||
38. Tularik filed to sell up to $250M in common stock and debt securities. It raised $27.2M in October 2002 with an offering of 4M shares. | ||||||
39. VaxGen filed a shelf registration statement for $150M in common stock, preferred stock, debt securities and warrants. Further details were not disclosed. | ||||||
40. Antex withdrew its registration statement for a proposed public offering of common stock and warrants after its underwriter said the company could not complete the offering within the time frame it had anticipated. | ||||||
41. Epimmune withdrew its public offering following its merger agreement with Anosys Inc. | ||||||